Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.

Currently viewing trials
(Last updated: August 03, 2020)

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 



Hormone Therapy

Radiation Oncology


Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment



Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children


Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence





NEAREST SITE: 1481 miles
Mays Cancer Center, UT Health San Antonio
San Antonio,TX

VISITS: 2 visits every 3 weeks, ongoing


NCT ID: NCT03995706

A Targeted Therapy for Breast Cancer That Has Spread to the Brain

A Phase 0, Investigator Initiated Study to Determine the Bioavailability of Sacituzumab Govitecan in Breast Brain Metastasis and Glioblastoma Scientific Title

To look at the safety of sacituzumab govitecan, an antibody-drug conjugate.
Who is this for?
People with metastatic (stage IV) breast cancer that has spread to the brain and scheduled to have surgery to remove the tumors in your brain.    Full eligibility criteria
Contact research site

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan, by IV, 1 day before surgery, then 2 times every 3 weeks following surgery, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan is an antibody-drug conjugate (ADC). </li> <li class="seamTextUnorderedListItem">These drugs combine an antibody that can target a cancer cell with an anti-cancer drug. </li> <li class="seamTextUnorderedListItem">The anti-cancer drug in sacituzumab govitecan is irinotecan, a chemotherapy drug used to treat many types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03995706' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Sacituzumab_govitecan' target='_blank'>Wikipedia: Sacituzumab Govitecan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancertodaymag.org/pages/Fall2015/Advances-Treating-Brain-Metastases.aspx' target='_blank'>Cancer Today: Breaking the Blood-Brain Barrier</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nejm.org/doi/full/10.1056/NEJMoa1814213' target='_blank'>The New England Journal of Medicine: Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer</a> </li></ul>
See more